All In Biotech

NDA 206995 · Astrazeneca

Iressa

Gefitinib · Oral · Kinase Inhibitor

Orphan

Last checked: Nov 19, 2026Latest source record: May 5, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2015

Jul 13, 2015

Approved uses

1

Original approval plus efficacy supplements

Registered trials

385

71 Phase 3, 6 recruiting

FAERS reports

8,993

8,525 serious, 1,955 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 28, 2023.

IRESSA is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test [see Clinical Studies (14) ] . Limitation of Use: Safety and efficacy of IRESSA have not been established in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations [see Clinical Studies (14) ] . IRESSA is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test. (1) Limitation of Use: Safety and efficacy of IRESSA have not been established in patients whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations. (1)

Mechanism: The epidermal growth factor receptor (EGFR) is expressed on the cell surface of both normal and cancer cells and plays a role in the processes of cell growth and proliferation. Some EGFR activating mutations (exon 19 deletion or exon 21 point mutation L858R) within NSCLC cells have been identified as contributing to the promotion of tumor cell growth, blocking of apoptosis, increasing the production of angiogenic factors and facilitating the processes of metastasis. Gefitinib reversibly inhibits the kinase activity of wild-type and certain activating mutations of EGFR, preventing...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 13, 2015 Original approval · Type 5 - New Formulation or New Manufacturer OrphanLetterLabelReview
1 products under this application
  • IRESSA · GEFITINIB 250MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Gefitinib" as an intervention, any sponsor and status, largest first.

All 385 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • malignant neoplasm progression1,824
  • drug resistance1,253
  • diarrhoea907
  • death758
  • rash643
  • disease progression462
  • interstitial lung disease420
  • nausea380
  • metastases to central nervous system377
  • dyspnoea332
  • vomiting326
  • drug ineffective299

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004801
2005515
20061,182
2007235
2008214
2009194
2010240
2011333
201287
201337
201448
2015239
2016503
2017557
2018614
2019990
2020713
2021430
2022278
2023283
2024249
2025181
202670

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Iressa (Gefitinib)

2024 spending

$1.3M

Beneficiaries

29

198 claims

Per beneficiary

$46,013

$235.13 per unit

View as table
YearSpending
2020$9,962,994
2021$7,349,915
2022$6,625,714
2023$3,529,858
2024$1,334,380

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 798 on PubMed

Sponsor: AstraZeneca

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.